reports
Capricor Therapeutics to Present Third Quarter 2025 Financial Results ...
Capricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10 Company to Host Conference Call on November 10, 2025, at 4:30 p.m. ET SAN DIEGO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that it will release its financial results for the third quarter ended September 30, 2025, after the market close on Monday, November 10, 2025. Management will then host a webcast and conference call at 4:30 p....
Corbus Pharmaceuticals Announces Pricing of Public Offering
Corbus Pharmaceuticals Announces Pricing of Public Offering NORWOOD, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), an oncology and obesity company, today announced the pricing of an underwritten public offering of 4,744,231 shares of its common stock at a public offering price of $13.00 per share, and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,025,000 shares of its common stock, at a public offering price of $12.9999 per pre-funded warrant, for a total public offering size of...
Corbus Pharmaceuticals Announces Proposed Public Offering
Corbus Pharmaceuticals Announces Proposed Public Offering NORWOOD, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), an oncology and obesity company, today announced that it plans to offer and sell shares of its common stock or, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock in an underwritten registered public offering. All of the securities in the offering are to be sold by Corbus. The offering is subject to market conditions, and there can be no assurance a...
NewtekOne, Inc. Reports 3Q25 and Year-to-Date 2025 Basic and Diluted E...
NewtekOne, Inc. Reports 3Q25 and Year-to-Date 2025 Basic and Diluted EPS of $0.68 and $0.67 and $1.57 and $1.54 Year-over-Year Quarterly and Year-to-Date Diluted EPS Growth Approximate 49% and 22% BOCA RATON, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- NewtekOne, Inc. (the "Company") (Nasdaq: NEWT) reports its financial and operating results for the three and nine month periods ended September 30, 2025. Financial Highlights for the three and nine months ended September 30, 2025: For the three months ended September 30, 2025 ("3Q25"), basic and diluted earnings per share ("EPS") were $0.68...
ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul...
ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group Appointment reinforces ProMIS Neurosciences’ strategic vision and deepens investor engagement as the Company advances its differentiated Alzheimer’s program, PMN310 Cambridge, Massachusetts, Oct. 22, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced that Slan...
- Wedbush Research
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
TSLA TESLA INC
TRIP TRIPADVISOR INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
PEGA PEGASYSTEMS INC.
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MU MICRON TECHNOLOGY INC.
MELI MERCADOLIBRE INC.
KURA KURA ONCOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
EXPE EXPEDIA GROUP INC.
ETSY ETSY INC.
EBAY EBAY INC.
BIIB BIOGEN INC.
AXTI AXT INC.
ARDX ARDELYX INC
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
ISR ISORAY
SE SEA ADS
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
BKNG BOOKING HOLDINGS INC.
LYFT LYFT
PINS PINTEREST INC. CLASS A
UBER UBER TECHNOLOGIES INC.
CHWY CHEWY INC. CLASS A
STOK STOKE THERAPEUTICS
SMCI SUPER MICRO COMPUTER
IDYA INC.
PRAX IDEAYA BIOSCIENCES
TVTX PRAXIS PRECISION MEDICINES
TLS TRAVERE THERAPEUTICS INC
DASH TELOS
ABNB DOORDASH
SNOW AIRBNB INC. CLASS A
STX SNOWFLAKE INC. CLASS A
VERA SEAGATE TECHNOLOGY HLDGS PLC
GFS VERA THERAPEUTICS INC
PL GLOBALFOUNDRIES INC
YOU PLANET LABS PBC
EWTX CLEAR SECURE INC
RUM EDGEWISE THERAPEUTICS INC
CRBP RUMBLE INC
CART CORBUS PHARMACEUTICALS HOLDINGS INC.
MAZE MAPLEBEAR INC.
JBIO MAZE THERAPEUTICS INC
JADE BIOSCIENCES INC
- Geoffrey Von Der Ahe
- Ritika Das
- Robert Driscoll
Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in H...
Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25 3.6 mg/kg dose generated ORR of 47.6% in HNSCC, 37.5% in cervical cancer and 55.6% in mUCCRB-701 continues to demonstrate a favorable safety and tolerability profileRegistrational studies planned to start in mid-2026Company to host an HNSCC KOL event during ESMO25 NORWOOD, Mass., Oct. 18, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company’) today announced data from its Phase 1/2 clinical study of CRB-701 (SYS6002) will be presente...
Corbus Pharmaceuticals to Present CRB-701 Phase 1/2 Data at ESMO 2025
Corbus Pharmaceuticals to Present CRB-701 Phase 1/2 Data at ESMO 2025 Data to be presented for 167 enrolled participants of which 122 were evaluable for efficacy Company to host HNSCC KOL event to review and discuss data NORWOOD, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical stage company focused on oncology and obesity, announced today the European Society for Medical Oncology (ESMO) Congress 2025 for its Phase 1/2 clinical study has been released. Updated data will be presented as a poster duri...
- Wedbush Research
RARE ULTRAGENYX PHARMACEUTICAL INC.
QLYS QUALYS INC.
PANW PALO ALTO NETWORKS INC.
NVCR NOVOCURE LTD.
NBIX NEUROCRINE BIOSCIENCES INC.
KURA KURA ONCOLOGY INC.
FTNT FORTINET INC.
CYBR CYBERARK SOFTWARE LTD.
CHKP CHECK POINT SOFTWARE TECHNOLOGIES LTD.
BIIB BIOGEN INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
ARDX ARDELYX INC
ISR ISORAY
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
ZS ZSCALER INC.
TENB TENABLE HOLDINGS
ARVN ARVINAS HOLDING
CRWD CROWDSTRIKE HOLDINGS INC. CLASS A
DDOG DATADOG INC CLASS A
APRE APREA THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
RVMD REVOLUTION MEDICINES
ORIC ORIC PHARMACEUTICALS
ZNTL ZENTALIS PHARMACEUTICALS
TVTX TRAVERE THERAPEUTICS INC
IMNM IMMUNOME
NUVB NUVATION BIO INC (A)
CGEM CULLINAN ONCOLOGY INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
FHTX FOGHORN THERAPEUTICS
TNGX TANGO THERAPEUTICS
TCRX INC
GLUE TSCAN THERAPEUTICS INC
S MONTE ROSA THERAPEUTICS INC
TYRA SENTINELONE INC
NUVL TYRA BIOSCIENCES INC
CRBP NUVALENT INC
RBRK CORBUS PHARMACEUTICALS HOLDINGS INC.
BCAX RUBRIK INC
BBOT BICARA THERAPEUTICS INC.
BRIDGEBIO ONCOLOGY THERAPEUTICS INC
- David Nierengarten
- Dennis Pak
- Geoffrey Von Der Ahe
- Martin Fan
- Ritika Das
- Robert Driscoll
ISR ISORAY
RCUS ARCUS BIOSCIENCES
ARVN ARVINAS HOLDING
IDYA IDEAYA BIOSCIENCES
RVMD REVOLUTION MEDICINES
ORIC ORIC PHARMACEUTICALS
IMNM IMMUNOME
NUVB NUVATION BIO INC (A)
CGEM CULLINAN ONCOLOGY INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
TCRX TSCAN THERAPEUTICS INC
TYRA TYRA BIOSCIENCES INC
NUVL NUVALENT INC
CRBP CORBUS PHARMACEUTICALS HOLDINGS INC.
BCAX BICARA THERAPEUTICS INC.
BBOT BRIDGEBIO ONCOLOGY THERAPEUTICS INC
- Wedbush Research
TPH TRI POINTE HOMES INC.
TOL TOLL BROTHERS INC.
NVCR NOVOCURE LTD.
KURA KURA ONCOLOGY INC.
ACRS ACLARIS THERAPEUTICS INC.
FRX_CN FENNEC PHARMACEUTICALS
TMHC TAYLOR MORRISON HOME CORPORATION
WVE WAVE LIFE SCIENCES
MHO M/I HOMES INC.
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
RCUS ARCUS BIOSCIENCES
KNSA KINIKSA PHARMACEUTICALS
IDYA IDEAYA BIOSCIENCES
BEAM BEAM THERAPEUTICS
NUVB NUVATION BIO INC (A)
CGEM CULLINAN ONCOLOGY INC
NUVL NUVALENT INC
PRME PRIME MEDICINE INC
CRBP CORBUS PHARMACEUTICALS HOLDINGS INC.
STUB STUBHUB HOLDINGS INC.
- David Nierengarten
- Dennis Pak
- Geoffrey Von Der Ahe
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Yun Zhong
ACRS ACLARIS THERAPEUTICS INC.
WVE WAVE LIFE SCIENCES
ANAB ANAPTYSBIO INC.
RCUS ARCUS BIOSCIENCES
IDYA IDEAYA BIOSCIENCES
BEAM BEAM THERAPEUTICS
NUVB NUVATION BIO INC (A)
CGEM CULLINAN ONCOLOGY INC
NUVL NUVALENT INC
PRME PRIME MEDICINE INC
CRBP CORBUS PHARMACEUTICALS HOLDINGS INC.
NewtekOne, Inc. to Report Third Quarter 2025 Results and Host a Confer...
NewtekOne, Inc. to Report Third Quarter 2025 Results and Host a Conference Call on Wednesday, October 29, 2025 BOCA RATON, Fla., Oct. 08, 2025 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: NEWT) will report its third quarter 2025 financial results after the market closes on Wednesday, October 29, 2025. A conference call to discuss these results will be hosted by Barry Sloane, Chief Executive Officer and Frank DeMaria, Chief Financial Officer of NewtekOne at 4:30 pm ET on Wednesday, October 29, 2025. Please note, to receive a dial-in number for the conference call or to listen to the webc...
Corbus Pharmaceuticals to Participate in the Upcoming Piper Sandler Vi...
Corbus Pharmaceuticals to Participate in the Upcoming Piper Sandler Virtual Oncology Symposium NORWOOD, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage oncology and obesity company, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a Fireside Chat at the Piper Sandler Virtual Oncology Symposium, to be held October 9-10, 2025. Piper Sandler clients can register for the event through their representative. Corbus Fireside ChatOctober 9, 2025, 10:00AM ETHo...
Newtek Merchant Solutions Obtains Term Facility and Line of Credit fro...
Newtek Merchant Solutions Obtains Term Facility and Line of Credit from Goldman Sachs Alternatives BOCA RATON, Fla., Sept. 30, 2025 (GLOBE NEWSWIRE) -- NewtekOne, Inc. (“NewtekOne” or “Company”) (NASDAQ: NEWT) announced that its wholly owned subsidiary, Newtek Merchant Solutions, LLC (“NMS”), has refinanced its term debt facility and revolving line of credit. Private Credit at Goldman Sachs Alternatives is providing NMS with a $90 million term loan facility and a $5 million line of credit. A portion of the proceeds funded the full repayment of NMS’s approximately $30 million of outstandin...
NewtekOne, Inc. Declares a Quarterly Dividend of $0.19 per Share
NewtekOne, Inc. Declares a Quarterly Dividend of $0.19 per Share BOCA RATON, Fla., Sept. 30, 2025 (GLOBE NEWSWIRE) -- (“the Company”) (NASDAQ: NEWT) announced that its Board of Directors declared a quarterly cash dividend of $0.19 per share on the outstanding common stock of NewtekOne. The dividend is payable on October 24, 2025, to shareholders of record as of October 14, 2025. Note Regarding Dividend Payments Amount and timing of dividends, if any, remain subject to the discretion of the Company's Board of Directors. About NewtekOne, Inc. , Your Business Solutions C...
PBF Energy Inc: 2 directors
Two Directors at PBF Energy Inc sold after exercising options/sold 110,000 shares at between 34.000USD and 34.134USD. The significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the...
NewtekOne, Inc. Declares Dividend on Series B Preferred Shares
NewtekOne, Inc. Declares Dividend on Series B Preferred Shares BOCA RATON, Fla., Sept. 29, 2025 (GLOBE NEWSWIRE) -- (“the Company”) (NASDAQ: NEWT) has declared a dividend on the Company’s outstanding 8.500% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series B (the “Preferred Shares”) in the amount of $9.44 per Preferred Share, or $0.2361 per depositary share, which is equivalent to 1/40th of the dividend on the Preferred Shares, payable on October 1, 2025 to holders of record as of September 29, 2025. This initial dividend payment on the Preferred Shares is pro-rated for t...
Capricor Therapeutics Provides Regulatory Update on Deramiocel Program...
Capricor Therapeutics Provides Regulatory Update on Deramiocel Program for Duchenne Muscular Dystrophy Following Type A Meeting FDA and Capricor aligned on endpoints for HOPE-3 pivotal trialHOPE-3 pivotal trial completed; topline data expected mid-Q4 2025 to support BLA resubmissionCompany preparing to resubmit CRL response under the current BLAConference call and webcast scheduled for today at 8:30 a.m. ET SAN DIEGO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today annou...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.